Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew S Davids

Showing results (151-160 of 225) with videos related to

Pageof 23
Sort By:
Blood Advances|March 26, 2026
A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter TransformationJennifer L Crombie, Christine E Ryan, Yue Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2023
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label TrialSikander Ailawadhi, Zi Chen, Bo Huang, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
Integrating Single-Cell Biophysical and Transcriptomic Features to Resolve Functional Heterogeneity in Mantle Cell LymphomaYe Zhang, Lydie Debaize, Adam Langenbucher, et al.
Science Advances|December 5, 2025
Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphomaYe Zhang, Lydie Debaize, Adam Langenbucher, et al.
Biorxiv : the Preprint Server for Biology|August 14, 2023
Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitorsRomanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Mairead Reidy, et al.
Leukemia|January 30, 2023
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemiaChristine E Ryan, Danielle M Brander, Paul M Barr, et al.
Blood Advances|January 30, 2024
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemiaStephan Stilgenbauer, Eugen Tausch, Andrew W Roberts, et al.
Blood|June 2, 2016
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicityBenjamin L Lampson, Siddha N Kasar, Tiago R Matos, et al.
Cancer Discovery|June 11, 2021
Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease HistoryLivius Penter, Satyen H Gohil, Caleb Lareau, et al.
Haematologica|February 25, 2021
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemiaChristoph Kornauth, Charles Herbaux, Bernd Boidol, et al.
Pageof 23

Showing results (151-160 of 225) with videos related to

Sort By:
Pageof 23
Blood Advances|March 26, 2026
A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter TransformationJennifer L Crombie, Christine E Ryan, Yue Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2023
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label TrialSikander Ailawadhi, Zi Chen, Bo Huang, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
Integrating Single-Cell Biophysical and Transcriptomic Features to Resolve Functional Heterogeneity in Mantle Cell LymphomaYe Zhang, Lydie Debaize, Adam Langenbucher, et al.
Science Advances|December 5, 2025
Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphomaYe Zhang, Lydie Debaize, Adam Langenbucher, et al.
Biorxiv : the Preprint Server for Biology|August 14, 2023
Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitorsRomanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Mairead Reidy, et al.
Leukemia|January 30, 2023
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemiaChristine E Ryan, Danielle M Brander, Paul M Barr, et al.
Blood Advances|January 30, 2024
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemiaStephan Stilgenbauer, Eugen Tausch, Andrew W Roberts, et al.
Blood|June 2, 2016
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicityBenjamin L Lampson, Siddha N Kasar, Tiago R Matos, et al.
Cancer Discovery|June 11, 2021
Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease HistoryLivius Penter, Satyen H Gohil, Caleb Lareau, et al.
Haematologica|February 25, 2021
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemiaChristoph Kornauth, Charles Herbaux, Bernd Boidol, et al.
Pageof 23